MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) in the treatment of seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial of efficacy and safety

Eli O. Meltzer* (Corresponding Author), Craig LaForce, Paul Ratner, David Price, David Ginsberg, Warner Carr

*Corresponding author for this work

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

Many patients with allergic rhinitis (AR) have uncontrolled symptoms despite available treatment options. This study was designed to evaluate the efficacy and safety of MP29-02 (a novel intranasal formulation of fluticasone propionate [FP] and azelastine [AZ] hydrochloride), compared with monotherapy with FP, AZ, and placebo sprays for the treatment of seasonal allergic rhinitis (SAR). This 2-week randomized, double-blind, placebo-controlled trial was conducted in 779 patients with moderate-to-severe SAR. Treatments were administered 1 spray/nostril twice daily in the same vehicle and delivery device. Daily doses of AZ and FP were 548 and 200 micrograms, respectively. The primary efficacy variable was the 12-hour reflective total nasal symptom score (rTNSS), consisting of nasal congestion, sneezing, itchy nose, and runny nose. Secondary efficacy variables were (1) 12-hour reflective individual nasal symptom scores; (2) onset of action; (3) 12-hour reflective total ocular symptom score (rTOSS), including itchy eyes, watery eyes, and red eyes; and (4) the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) overall score. MP29-02 significantly reduced the mean rTNSS from baseline by −5.54 points compared with FP (−4.55; p = 0.038), AZ (−4.54; p = 0.032), and placebo (−3.03; p < 0.001), improving the rTNSS by 39% beyond the contribution of FP. All individual nasal symptoms contributed to the efficacy of MP29-02. Onset of action was within 30 minutes. MP29-02 significantly improved rTOSS compared with placebo, provided a clinically important improvement in the overall RQLQ score, and was well tolerated. In this study, MP29-02 provided more complete symptom relief than two widely used first-line AR treatments and was well tolerated.
Original languageEnglish
Pages (from-to)324-332
Number of pages9
JournalAllergy and Asthma Proceedings
Volume33
Issue number4
DOIs
Publication statusPublished - 1 Jul 2012

Keywords

  • Active-controlled
  • MP29-02
  • Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)
  • allergic rhinitis
  • azelastine hydrochloride
  • clinical trial
  • double-blind
  • fluticasone propionate
  • placebo-controlled
  • randomized
  • rhinitis treatment
  • total nasal symptom score (TNSS)
  • total ocular symptom score (TOSS)

Fingerprint Dive into the research topics of 'MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) in the treatment of seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial of efficacy and safety'. Together they form a unique fingerprint.

  • Cite this